English

HONGKONG XINCHENG GONGCHUANG TECHNOLOGY CO., LTD.

HONGKONG XINCHENG GONGCHUANG TECHNOLOGY CO., LTD.

Home > Products > Pharmaceutical Raw Materials > Pharmaceutical Raw Materials Tyrosine Kinase Inhibitor Gefitinib Raw Powder for
 

Pharmaceutical Raw Materials Tyrosine Kinase Inhibitor Gefitinib Raw Powder for

  • Pharmaceutical Raw Materials Tyrosine Kinase Inhibitor Gefitinib Raw Powder for
Place of Origin:
China
Brand Name:
GONGCHUANG
Certification:
ISO9001,USP,KOSHER,etc
Model Number:

SARM

Min.Order Quantity:
10gram
Price:
negotiable
Packaging Details:
25k/Drum
Delivery Time:
arrange package within 2working days after payment
Payment Terms:
T/T, Western Union, MoneyGram,bitcoin
Supply Ability:
500kg+ each week
Contact Now
 

Product Description

Pharmaceutical Raw Materials Tyrosine Kinase Inhibitor Gefitinib Raw Powder for Anti-Cancer

Selective Inhibitor Gefitinib CAS 184475-35-2 Anticancer Ingredients

Product Name: Gefitinib
Synonyms: IRESSA;GEFITINIB;AKOS 91371;n-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine;N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinamine;ZD 1839;4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-;Gefitinib(TINIBS)
CAS: 184475-35-2
MF: C22H24ClFN4O3
MW: 446.9

Gefitinib Usage

Gefitinib is a kind of selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase.
The recommended treatment dose of adult is 250 mg of (1 tablet) with 1 time per day through orally administration, either in empty stomach or together with food.
If you have difficulty in swallowing, you can disperse the tablets into a half cup of drinking water (non-carbonated beverages). Make sure to avoid using other kinds of liquid. Cast tablets into the water and stir until the complete dispersion of the tablet in the water (takes about 10 minutes) without the necessity of crushing. Immediately drink the liquid, and use half glass of water to rinse the cup, drink again. Alternatively, you can also administrate this drug solution through the nose-stomach tube.
There is no necessity in adjusting the administrated dosage of the drug: age, weight, gender, race, renal function, and moderate to severe liver function dysfunction caused by hepatic metastasis.
Dose adjustment: when patients can tolerate the diarrhea or skin adverse reactions, you can tackle this issue through short-term suspension (up to 14 days) of the treatment and then restore the dose of 250 mg per day.

Chemical Properties Light-Yellow Crystalline Powder
Usage Gefitinib (Iressa, ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.
Usage Gefitinib is an antineoplastic.

Gefitinib Side effects

It has a better tolerability with most adverse reaction being minor and reversible, and is totally different from typical adverse reactions of cytotoxic drug. Common adverse reactions include diarrhea, nausea, rashes, acne, vomiting and weakness with the incidence being over 20%. The ratio of patents who stops the treatment because of the adverse drug reactions is only 1%. Sometimes acute interstitial pneumonia can happen occasionally which can even cause death of some patients. Therefore, if enhanced respiratory symptoms such as shortness of breath, cough and fever happen in the patients, should immediately discontinue the treatment, and find out whether it is interstitial pneumonia. Gefitinib is not suitable for applied to women during pregnancy. Lactation women should stop breastfeeding during the treatment.

DMHA / 1,5-Dimethylhexylamine
 
DMAA / 1,3-Dimethylpentylamine
 
DMAE bitartrate / 2-Dimethylaminoethanol bitartrate salt
 
Orlistat
Pregabalin
Isotretinoin
Benzyl benzoate
Benzyl alcohol
Ethyl Oleate
4-Acetamidophenol / Paracetamol
Guaiacol
Tranexamic acid / Amstat
Noopept
 
Raloxifene hydrochloride
Synephrine hydrochloride
Lorcaserin hydrochloride hemihydrate
Triamcinolone acetonide acetate
Xylazine
Aniracetam
Piracetam
Oxiracetam
Pramiracetam
Fasoracetam
Triclosan
Ibuprofen
Captopril
Adrenosterone / 11-OXO
Androsterone
Pramipexole Hydrochloride
 
Apremilast (CC-10004) / Otezla
 

Tyrosine Kinase Inhibitor Gefitinib Raw Powder for Anti-Cancer
Gefitinib

Product Name: Gefitinib
Synonyms: IRESSA;GEFITINIB;AKOS 91371;n-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
CAS: 184475-35-2
MF: C22H24ClFN4O3
MW: 446.9
Purity: 99.5%
Appearance: White powder
Grade : Pharmaceutical Grade

Usage Gefitinib is a kind of selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase.

The recommended treatment dose of adult is 250 mg of (1 tablet) with 1 time per day through orally administration, either in empty stomach or together with food.

If you have difficulty in swallowing, you can disperse the tablets into a half cup of drinking water (non-carbonated beverages). Make sure to avoid using other kinds of liquid. Cast tablets into the water and stir until the complete dispersion of the tablet in the water (takes about 10 minutes) without the necessity of crushing. Immediately drink the liquid, and use half glass of water to rinse the cup, drink again. Alternatively, you can also administrate this drug solution through the nose-stomach tube.

There is no necessity in adjusting the administrated dosage of the drug: age, weight, gender, race, renal function, and moderate to severe liver function dysfunction caused by hepatic metastasis.

Dose adjustment: when patients can tolerate the diarrhea or skin adverse reactions, you can tackle this issue through short-term suspension (up to 14 days) of the treatment and then restore the dose of 250 mg per day.


Pharmacokinetic It is effective through oral administration with a low metabolism rate after the oral absorption. A single oral administration of 250 mg has a bioavailability being close to 60%. During the medication, the area under the curve (AUC) was dose related. After administration of 1 times per day, it reaches steady-state blood drug concentration after the treatment of 7~10 days with the plasma concentration peak occurring at 3~7 hours after the administration, then the blood drug concentration gradually reduces in two phase (half-life: 12~58 hours with average time of 28 hours), and is characterized by dose dependent pharmacokinetic which means that AUC and Cmax increase in proportion to each other with multiple dosing. However, when taking it together with food, its Cmax and AUC did not significantly reduced. It has a plasma protein bind rate being nearly 90%. Gefitinib is metabolized in liver by multiple and complicated metabolic pathways. The enzyme which participates in its oxidative metabolism is mainly the CYP3A4 in the cytochrome P450 enzyme system whose major metabolites are O-dimethyl substance. The metabolites have nothing to do with the pharmacology of the prototype drug. The prototype drug and most of the metabolites are mainly excreted through the biliary drainage and are discharged out of the body through feces. The metabolites excreted through urinary excretion only accounts for lower than 4% of the dosage.

 

Pharmaceutical Raw Materials Tyrosine Kinase Inhibitor Gefitinib Raw Powder for Images

 

Send Inquiry

*Email

Please Enter your Email Address

Subject

Inquiry About

Quick question
Please select FAQ

I'm very interested in your products; could you send me some detail reference information?

Please send me detail product specification, thank you!

May I be an agency of your products,and what's yourterms?

We intend to purchase this product, would you please send me the quotation and minimum order quantity?

*Message
I want to buy

For the best results, we recommend including the following details: -Self introduction -Required specifications -Inquire about price/MOQ